A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
This study is an extension of an earlier trial looking at a medicine called Acoramidis for a heart condition called variant transthyretin amyloid cardiomyopathy. This condition happens when certain proteins build up in the heart, making it harder for the heart to pump blood. In this ongoing study, participants who were already taking Acoramidis will continue to receive it. The main goal is to keep an eye on safety, checking for any side effects or changes in their health. Researchers will also be looking at important heart measures, like how often people need to go to the hospital for heart issues, and how the medicine affects their overall heart health and well-being over time.
Em resumo
Sobre o que é este estudo?
This study is about a medicine called Acoramidis, and it's for people who have recently been diagnosed with a type of heart condition called variant transthyretin amyloid cardiomyopathy. In simple terms, this condition occurs when a specific protein, which normally helps carry things in your blood, starts to misbehave. Instead of doing its job properly, it forms clumps (called amyloid) and deposits them in your heart. This makes your heart muscle stiff and thick, making it harder for it to pump blood around your body effectively. This can lead to various heart problems.
This particular study is an 'extension' study. This means that people who were already taking Acoramidis in an earlier part of the trial will continue to receive it. The main reason for this extension is to get a much longer-term picture of how safe the medicine is. Doctors want to understand if there are any side effects that only show up after taking the medicine for a while, and if it continues to be well-tolerated. They'll be checking your general health, vital signs like blood pressure, and specific heart tests regularly.
Beyond just safety, the study also aims to see how well Acoramidis helps with the heart condition over time. They will be looking at things like hospital admissions for heart issues, how the heart is functioning, and even general well-being. This information helps doctors understand the long-term benefits and risks, which is really important for deciding if a medicine is good for patients in the long run.
Pontos principais
- This is an extension study for people already taking Acoramidis.
- It focuses on the long-term safety and effects of the medicine.
- The condition being studied is variant transthyretin amyloid cardiomyopathy, a heart condition.
- Participation involves regular health checks and heart tests.
- The study aims to understand the medicine's impact on heart health over time.
Quem pode ser elegível?
To join this particular study, you would need to have been part of an earlier trial and already be taking the medicine Acoramidis. This is an extension of that previous study.
The study is for adults aged 18 years and older. Both men and women can take part.
Since this is an extension, you would generally need to have tolerated the medicine well and met certain health criteria during the first part of the study to continue.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Were you previously part of a study for Acoramidis?
- Are you currently taking Acoramidis as part of a study?
- Você tem 18 anos ou mais?
- Do you have a diagnosis of variant transthyretin amyloid cardiomyopathy?
O que envolve a participação?
As this is an extension study, you would continue to take the study medicine, Acoramidis. You would have regular visits to the clinic, where doctors and nurses would check your health carefully. These checks would include physical examinations, taking your blood pressure and pulse, and doing blood tests. You'd also have heart tests, like an ECG (which checks your heart's electrical activity) and possibly echocardiograms (ultrasound scans of your heart) to see how your heart is working. The study is 'open-label,' meaning both you and your doctor will know you are receiving Acoramidis. The total duration of your participation would depend on how long the extension study is planned to run, but these types of studies typically involve ongoing monitoring over several months or even years.
Riscos e benefícios potenciais
Localizações (11)
- —Não verificadoAlemanha
- —Não verificadoPortugal
- —Não verificadoPaíses Baixos
- —Não verificadoFrança
- —Não verificadoEspanha
- —Não verificadoItália
- —Não verificadoIrlanda
- —Não verificadoBélgica
- —Não verificadoSuécia
- —Não verificadoDinamarca
- —Não verificadoGrécia
Perguntas frequentes
What is variant transthyretin amyloid cardiomyopathy?
It's a heart condition where a faulty protein builds up in the heart, making it stiff and weaker over time.
What is Acoramidis?
It's the name of the medicine being studied, designed to help with this specific heart condition.
O que significa 'Fase 3' para um estudo?
It means the medicine has already shown promise in earlier studies, and this phase is to confirm its safety and effectiveness in a larger group of people.
Saberei se estou recebendo o medicamento real?
Yes, in this 'open-label' study, both you and your doctors will know you are taking Acoramidis.
Posso parar de participar se eu quiser?
Yes, you have the right to leave the study at any time, for any reason, without it affecting your medical care.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.